Sekėjai

Ieškoti šiame dienoraštyje

2020 m. lapkričio 18 d., trečiadienis

Changes in Covid-19 treatment

 "Early treatment protocols at many hospitals included giving patients the antimalaria drug hydroxychloroquine, which was later found not to be beneficial, Dr. Shapiro said. Other steps included using anticoagulants to help patients avoid blood clots.

Doctors are now informed by peer-reviewed papers from around the world, clinical trials and the Food and Drug Administration's emergency clearance of some treatments. Promising treatments for hospitalized patients include the antiviral remdesivir and convalescent plasma. Steroids such as dexamethasone have been shown in testing to be effective at tamping down the immune-system overdrive.

On Nov. 9, the FDA authorized the use of an antibody drug developed by Eli Lilly & Co. to treat people with Covid-19 in earlier stages, filling a gap in treatment for patients who aren't hospitalized.

A crucial difference in hospital treatment has stemmed from a better understanding of how to approach respiratory problems. Instead of rushing to put patients with low oxygen saturation on ventilators, which brings risks, doctors now know that people with low oxygen levels can remain that way longer than previously thought, Dr. Bankhead-Kendall said. For the most critically ill who do require ventilation, hospitals are expanding the use of technology to monitor those patients. Studies have shown, for example, the importance of carefully managing ventilator settings." [1]


1. U.S. News: As Cases Surge, Doctors Refine Treatments
Krouse, Sarah. Wall Street Journal, Eastern edition; New York, N.Y. [New York, N.Y]18 Nov 2020: A.7.

Komentarų nėra: